ERBB2 and breast carcinoma: Similar results were obtained from an IHC study in which 57% of triple-negative breast cancers stained highly positive for ROR1, whereas signals were detected in only 12% of the estrogen receptor (ER) and progesterone receptor (PR)-positive patients, and no expression at all was found in Her2/Neu-positive breast cancers [25].